Andrzej Jakubowiak
Section of Hematology / Oncology
Professor of Medicine
Director, Myeloma Program
Referring Physician Access Line: 1-877-DOM-2730


MD1977Medical Academy, Poznan, PolandMedicine
PhD1983Medical Academy, Poznan, PolandHistology and Embryology
Residency1984Medical Academy, Institute of Internal Medicine, Poznan, PolandMedicine
Fellowship1992The University of Texas Medical SchoolObstetrics, Gynecology and Reproductive Sciences
Residency1993The University of Texas Medical SchoolPathology
Residency1997The University of TexasMedicine
Fellowship2000Joan and Stanford I. Weill Medical College of Cornell UniversityMedicine
Fellowship2000Memorial Sloan-Kettering Cancer Center, NY, NYMedical Oncology/Hematology

Academic Interests

Dr. Jakubowiak is an internationally known expert on multiple myeloma, a cancer of the plasma cells in a patient’s bone marrow. He works closely with the Multiple Myeloma Research Consortium (MMRC) to bring the latest treatments to the patient’s bedside as quickly as possible. Dr. Jakubowiak’s primary research focus is in the development of new drugs for the treatment of multiple myeloma. He is currently the lead investigator on a number of multi-site clinical trials for patients who are newly diagnosed, have relapsed, or have refractory (resistant to treatment) disease.

Clinical Interests

Multiple myeloma, Lymphoma, and Non-Hodgkins Lymphoma

Representative Publications

  1. Smith SM. Non-myeloablative Transplantation for Lymphoma. Current Treat Options Oncol, 2003 Aug;4(4):261-8.
  2. Smith SM and van Besien K. Mediastinal lymphomas. In Textbook of Cardiothoracic Surgery, in press.
  3. Smith SM, Grinblatt DL, Van Besien, K. Autologous and Allogeneic Transplantation for aggressive non-Hodgkin’s lymphomas. Cytotherapy 4(3):223, 2002.
  4. Smith SM, LeBeau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-Cytogenetic Associations in 306 Patients with Therapy-Related Myeloid Leukemia (t-AML) at the University of Chicago. Blood, 2003 Jul 1;102 (1):43-52.
  5. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible Myelosuppression after Fludarabine-Melphalan conditioning: Observations in Patients with Graft Rejection. Letter to the editor, Blood 2004 June 1;103(11):4373-4

More Information

For more information about Dr. Andrzej Jakubowiak publications and research collaborations , please click here